RxDoctor Payments Data

Muhammad Umair Mushtaq, MD

Hematology & Oncology · Westwood, KSNPI 1245646397

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Sanofi at 51.1% of the total. 2025 is the largest year on record at $12,262, 4.5 times the $2,747 reported in 2022.

$20,697in general payments, 2019–2025

Across 32 payments — averaging $646.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$11K
  • National Marrow Donor Program$7K
  • Johnson & Johnson$2K
  • Genentech USA, Inc.$2K
  • Beigene USA, Inc.$70
  • AbbVie$34
$588,126in research payments, 2019–2025

Across 30 payments — averaging $19,604 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Iovance Biotherapeutics, Inc.$498K
  • Incyte Corporation$37K
  • National Marrow Donor Program$34K
  • Genentech, Inc.$20K

What the payments were for

  • Consulting fees$9,25145%
  • Speaking & faculty fees$1,8569%
  • Travel & lodging$7,76538%
  • Food & beverage$1,8259%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,697 in reported general payments places this provider in the 70th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$124,072
Medicare patients
190
Services billed
1,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ShingrixVaricella-Zoster Ge/As01b/Pf20$3,632
Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf24$3,632
PentacelDipht,pert(A),tet-Polio/Hib/Pf33$3,415
Acyclovir86$980
Hydrocortisone33$835
Entecavir11$659
Dapsone12$470
Duloxetine Hcl25$426
Rosuvastatin Calcium24$425
Carvedilol36$334
Prochlorperazine Maleate17$275
Gabapentin11$241
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim41$142
Pantoprazole Sodium12$138
Oxycodone Hcl19$131

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →